{
    "clinical_study": {
        "@rank": "30272", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A - Capecitabine and ruxolitinib", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment B - Capecitabine and placebo", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, placebo controlled clinical trial comparing the overall\n      survival of women with advanced or metastatic HER2-negative breast cancer who receive\n      treatment with capecitabine in combination with ruxolitinib versus those who receive\n      treatment with capecitabine alone."
        }, 
        "brief_title": "A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced or Metastatic HER2-negative Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed HER2-negative adenocarcinoma of the breast\n\n          -  Locally advanced (Stage 3B) or metastatic (Stage 4) disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n\n          -  Received up to 2 prior chemotherapy regimens (not including neoadjuvant/adjuvant\n             therapy) for advanced or metastatic disease\n\n          -  Subjects with hormone-receptor positive tumors must have failed available appropriate\n             lines of hormonal therapy\n\n          -  \u2265 2 weeks elapsed from the completion of previous treatment regimen and must have\n             recovered or be at a new stable baseline from any related toxicities\n\n          -  Radiographically measurable or evaluable disease\n\n        Exclusion Criteria:\n\n          -  Received prior treatment with capecitabine\n\n          -  Received more than 2 prior chemotherapy regimens for advanced or metastatic disease\n             (not including neoadjuvant/adjuvant therapy)\n\n          -  Unknown hormone-receptor status\n\n          -  Bilateral breast cancer or a history of 2 distinct breast cancers\n\n          -  Inflammatory breast carcinoma\n\n          -  Ongoing radiation therapy, radiation therapy administered within 2 weeks of\n             enrollment, or history of radiation therapy to \u2265 25% of the bone marrow"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "148", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02120417", 
            "org_study_id": "INCB 18424-268"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A - Capecitabine and ruxolitinib", 
                "description": "5 mg tablets to be administered by mouth\nRuxolitinib 15 mg BID (starting dose)", 
                "intervention_name": "Ruxolitinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Jakafi \u00ae", 
                    "Jakavi \u00ae"
                ]
            }, 
            {
                "arm_group_label": [
                    "Treatment A - Capecitabine and ruxolitinib", 
                    "Treatment B - Capecitabine and placebo"
                ], 
                "description": "Capecitabine 2000 mg/m^2 daily given as 1000 mg/m^2 BID (starting dose)", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B - Capecitabine and placebo", 
                "description": "5 mg matching placebo tablets to be administered by mouth", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Breast Cancer", 
        "lastchanged_date": "April 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chandler", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plantation", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Savannah", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Billings", 
                        "country": "United States", 
                        "state": "Montana"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Camden", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Canton", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Germantown", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Green Bay", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer", 
        "overall_contact": {
            "last_name": "Incyte Corporation Call Center", 
            "phone": "1-855-463-3463"
        }, 
        "overall_official": {
            "affiliation": "Incyte Corporation", 
            "last_name": "Gerard Kennealey, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall Survival (OS)", 
            "safety_issue": "No", 
            "time_frame": "Randomization until death due to any cause. Approximately 29 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02120417"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PFS is defined as the time from randomization through until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) (v1.1)., or death due to any cause if sooner.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Randomization to disease progression, or death due to any cause if sooner. Approximately 29 months."
            }, 
            {
                "description": "Objective Response Rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment.", 
                "measure": "Objective Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline through end of study. Approximately 29 months."
            }, 
            {
                "description": "Clinical benefit rate defined as a complete response, partial response, or stable disease, determined by investigator assessment of objective radiographic disease assessments per RECIST (v1.1) that lasts for \u2265 6 months.", 
                "measure": "Clinical Benefit Rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline through end of study. Approximately 29 months."
            }, 
            {
                "measure": "Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through approximately 30 days post treatment discontinuation. Approximately 29 months."
            }, 
            {
                "description": "Duration of response determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment", 
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Baseline through end of study. Approximately 29 months."
            }
        ], 
        "source": "Incyte Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Incyte Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}